BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension
PULMONARY CIRCULATION(2024)
摘要
Bone morphogenetic protein receptor 2 (BMPR2) mutation is the most common gene mutation implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We describe, for the first time, an excellent clinical response to tyrosine kinase inhibitor imatinib in a patient with heritable PAH from BMPR2 mutation.
更多查看译文
关键词
Bmpr2 mutation,hereditary,imatinib,pulmonary hypertension
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要